2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. MAP4K
  5. MAP4K1/HPK1 Isoform

MAP4K1/HPK1

 

MAP4K1/HPK1 Related Products (23):

Cat. No. Product Name Effect Purity
  • HY-138568
    HPK1-IN-3
    		Inhibitor 99.32%
    HPK1-IN-3 is a potent and selective ATP-competitive hematopoietic progenitor kinase 1 (HPK1; MAP4K1) inhibitor with an IC50 of 0.25 nM. HPK1-IN-3 has IL-2 cellular potency with an EC50 of 108 nM in human peripheral blood mononuclear cells (PBMCs).
  • HY-138742
    HPK1-IN-7
    		Inhibitor 99.33%
    HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC50=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1.
  • HY-157149
    DS21150768
    		Inhibitor 99.26%
    DS21150768 is a potent, orally active HPK1 inhibitor. DS21150768 shows potent activity to enhance T-cell function. DS21150768 has anticancer effects.
  • HY-144088
    ZYF0033
    		Inhibitor 98.86%
    ZYF0033 is effective in inhibiting hematopoietic progenitor cells HPK1, basically inhibiting MBP protein oxidation IC50 10 nM . ZYF0033 promotes anti-cancer immune response, lowers SLP76 (acid 376) oxidation. ZYF0033 Suppression 4T-1 Small mouse model with the same underlying cause, medium bulge growth length expansion DC, NK 细细和 CD107a+ CD8+ T Cells, PD-1+CD8+ T Cells, TIM-3+CD8+ T Cells LAG3< sup>+CD8+ T Cellular immersion decreases.
  • HY-148847
    HPK1-IN-32
    		Inhibitor 98.12%
    HPK1-IN-32 is a potent and selective HPK1 inhibitor with an IC50 of 65 nM. HPK1-IN-32 can be used for the research of HPK1 related disorders or diseases.
  • HY-172107
    HPK1-IN-56
    		Inhibitor
    HPK1-IN-56 (Compound A29) is a HPK1 inhibitor (IC50: 2.70 nM). HPK1-IN-56 inhibits downstream p-SLP76 (IC50: 8.1 nM in Jurkat T cells). HPK1-IN-56 induces the production of IL-2 in human PBMCs. HPK1-IN-56 has anticancer effect, enhances T-cell killing ability and the antitumor efficacy of anti-PD-1 antibody.
  • HY-168110
    HPK1-IN-52
    		Inhibitor
    HPK1-IN-52 is a potent and orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC50 value of 10.4 nM. HPK1-IN-52 exhibits anti-tumor activities.
  • HY-170365
    HPK1-IN-55
    		Inhibitor
    HPK1-IN-55 (compound 19) is a selective and orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC50 of <0.51 nM. HPK1-IN-55 shows excellent kinase selectivity (>637-fold vs GCK-like kinase and >1022-fold vs LCK). HPK1-IN-55 has anticancer effects.
  • HY-144093
    HPK1-IN-26
    		Inhibitor ≥98.0%
    HPK1-IN-26 is a HPK1 and GLK inhibitor extracted from patent WO2021254118A1 compound 1. HPK1-IN-26 can be used for the research of animal pathogen infection.
  • HY-148061
    DB1113
    		99.28%
    DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity.
  • HY-153362
    HPK1-IN-34
    		Inhibitor
    HPK1-IN-34 (Compound 143) is a Hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC50 of <100 nM. HPK1-IN-34 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-149056
    GNE-6893
    		Inhibitor 99.94%
    GNE-6893 is a potent and orally active HPK1 inhibitor. GNE-6893 can be used in research of cancer.
  • HY-146231
    SS47
    SS47, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the antitumor efficacy.
  • HY-159123
    KHK-6
    		Inhibitor
    KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC50 of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells.
  • HY-144073
    HPK1-IN-21
    		Inhibitor
    HPK1-IN-21 is a potent inhibitor of HPK1 kinase inhibitor (Ki=0.8 nM). HPK1-IN-21 also has orally active.
  • HY-153448
    HPK1-IN-36
    		Inhibitor
    HPK1-IN-36 (compound 2) is a potent HPK1 inhibitor with an IC50 value of 0.5 nM.
  • HY-163495
    HPK1-IN-44
    		Inhibitor
    HPK1-IN-44 (Compound 1) is an inhibitor of HPK1 (IC50=0.1 nM (40 μM ATP)).
  • HY-149232
    HPK1-IN-35
    		Inhibitor
    HPK1-IN-35 is a potent and selective HPK1 inhibitor with an IC50 value of 3.5 nM. HPK1-IN-35 decreases the expression of p-SLP76 and promotes IL-2 secretion.
  • HY-161917
    HPK1-IN-49
    		Inhibitor
    HPK1-IN-49 (Compound I-4) is an inhibitor for hematopoietic progenitor kinase 1 (HPK1) with an IC50 >100 nM.
  • HY-144091
    HPK1-IN-24
    		Inhibitor
    HPK1-IN-24 (example 51) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with a Ki of 100 nM. HPK1-IN-24 has the potential for cancer research.